We engineered CD8+ T cells with two orthogonal cytokines for adoptive cell transfer into mice with solid tumors. These cells acquired a novel synthetic effector state that fully deviated from TOX+ canonical exhaustion and displayed improved anti-tumor effector functions.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610, 173–181 (2022). A fundamental study defining the mechanisms by which IL-2 acts in synergy with PD-1 blockade to modify CD8+ T cell exhaustion.
Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature 610, 161–172 (2022). A seminal study demonstrating the generation of non-canonical improved effector cells after systemic administration of anti-PD-1–IL-2v treatment.
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019). A seminal study demonstrating that TOX is the transcriptional and epigenetic master regulator of CD8+ T cell exhaustion.
Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230–6238 (2013). Outstanding work demonstrating the anti-tumor efficacy of systemic administration of IL-2v.
Villarreal, D. O. et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 74, 1789–1800 (2014). Outstanding work demonstrating that IL-33 can be an effective adjuvant to drive CD8-mediated protective immunity against cancer.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Corria-Osorio, J. et al. Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. Nat. Immunol. https://doi.org/10.1038/s41590-023-01477-2 (2023).
Rights and permissions
About this article
Cite this article
Generation of a novel synthetic CD8+ T cell state that leads to tumor control in mice. Nat Immunol 24, 755–756 (2023). https://doi.org/10.1038/s41590-023-01478-1